课题基金 / 基金详情

A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER

A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER
GARFT 抑制剂 AG2034 在晚期癌症患者中的 I 期研究
批准号：
6113677
负责人：
DARCY V SPICER
金额：
$3.56万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6113677
关键词：
clinical research clinical trial phase I dosage drug screening /evaluation enzyme inhibitors folate human subject human therapy evaluation hydroxymethyltransferases neoplasm /cancer chemotherapy pharmacokinetics purine /pyrimidine metabolism purines

项目摘要

项目成果

DARCY V SPICER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
GARFT is an enzyme essential in the pathway for de novo synthesis of purines. AG2034 is a novel inhibitor of GARFT. This study will evaluate the safety and dose tolerance of AG2034 when given IV to patients with advanced cancer. The pharmacokinetics and pahrmacodynamics for AG2034 using indicator of folate and purine status and cellular retention of drug-matabolites will be studied. Any antitumor effects will be documented. The maximum dose and dose-limiting toxicities will be determined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SCCISARS 2: An e-Solution to Protect Human Subjects
A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER
PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER
海外基金